Samarth Kulkarni Sells 9,973 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 9,973 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $423,054.66. Following the sale, the chief executive officer now directly owns 180,890 shares of the company’s stock, valued at approximately $7,673,353.80. The trade was a 5.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Samarth Kulkarni also recently made the following trade(s):

• On Wednesday, February 19th, Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00.

CRISPR Therapeutics Stock Performance

Shares of CRSP traded up $1.12 during trading hours on Wednesday, hitting $43.49. The stock had a trading volume of 1,399,700 shares, compared to its average volume of 2,256,949. The firm has a 50-day moving average price of $43.02 and a 200 day moving average price of $45.65. CRISPR Therapeutics AG has a fifty-two week low of $36.52 and a fifty-two week high of $76.86. The firm has a market capitalization of $3.73 billion, a price-to-earnings ratio of -9.95 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Hedge Funds Weigh In On CRISPR Therapeutics

Large investors have recently bought and sold shares of the business. Wood Tarver Financial Group LLC purchased a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $30,000. Ameriflex Group Inc. acquired a new stake in CRISPR Therapeutics in the 4th quarter valued at $36,000. Highline Wealth Partners LLC purchased a new stake in CRISPR Therapeutics in the 4th quarter worth $39,000. Western Pacific Wealth Management LP raised its position in CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after acquiring an additional 500 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new position in CRISPR Therapeutics during the third quarter valued at $40,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on CRSP. Evercore ISI upgraded shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and raised their target price for the company from $60.00 to $99.00 in a research note on Friday, February 14th. Stifel Nicolaus dropped their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a research note on Thursday, February 13th. Royal Bank of Canada decreased their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 12th. Needham & Company LLC reissued a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Finally, Barclays upped their price objective on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $73.11.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.